Date posted: May 19, 2015, 6:00 am
In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 1 of a 2 part episode.
Date posted: April 28, 2015, 6:00 am
In this episode, we interview Brad Cannon, PharmD regarding his career path in pharmacy and his viewpoints on the pharmacy profession.
Date posted: April 7, 2015, 6:00 am
In this episode, we discuss the optimal drug therapy for three different case vignettes -- depression, hypertension, and diabetes mellitus.
Date posted: March 16, 2015, 6:00 am
In this episode, we review historical and new treatment options for hepatitis C, including: peginterferon, rivabirin, boceprevir, telaprevir, sofosbuvir (Sovaldi), simeprevir (Olysio), ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak), and ledipasvir/sofosbuvir (Harvoni).
May 18, 2015 - Correction added in the beginning of the episode regarding Viekira Pak dosing regimen.
Date posted: March 3, 2015, 6:00 am
In this episode, we discuss the pharmacology of oversedation, the importance of sedation minimization strategies in mechanically ventilated patients, and overview the sedatives and analgesics commonly used in this patient population.
Date posted: February 10, 2015, 6:00 am
In this episode, we discuss risk factors for opioid-related adverse events, naloxone (Narcan, Evzio), and a number of non-narcotic agents for neuropathic pain.
Date posted: January 20, 2015, 6:00 am
In this episode, we summarize and discuss the clinical implications of the SMART trial (Salmeterol Multicenter Asthma Research Trial; Nelson et al, 2006).
Date posted: December 16, 2014, 6:00 am
In this episode, we discuss two controversial topics in the world of immunizations with Dr. Angelo -- the "high-dose" influenza vaccine and the expanded use of PCV13 (Prevnar-13).
Date posted: December 2, 2014, 6:00 am
In this episode, we review HIV therapy with Dr. Cottreau with a particular focus on Truvada, Atripla, Complera, Stribild, and Triumeq.
Date posted: November 18, 2014, 6:00 am
In this episode, we discuss the management of overactive bladder, including: oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), trospium (Sanctura), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq), and onabotulinumtoxinA (Botox).